Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced positive data for NPM-139, its subdermal semaglutide implant for ...

Vivani Medical (VANI) has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of ...

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant ...

Enables accelerated development of NPM-139, Company’s once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE ...

Values are mean ± SE. Source: Vivani Medical, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...

Shares of Vivani Medical stock opened at $1.15 on Wednesday. The firm has a 50-day moving average of $1.14 and a 200-day moving average of $1.21. Vivani Medical has a 52-week low of $1.03 and a 52 ...

March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani” or the "Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, ...

On Thursday, H.C. Wainwright analyst Yi Chen maintained a Buy rating and a $4.00 price target on Vivani Medical, Inc. (NASDAQ: VANI), currently trading at $1.12 with a market capitalization of $66 ...